News & Updates

In the treatment of patients with refractory cutaneous dermatomyositis, the cannabinoid receptor type 2 agonist lenabasum yields good outcomes in terms of efficacy and safety, as indicated by improvements in disease activity and no increased risk of serious or severe adverse events, according to the results of a phase II study.

Long-term findings from the pooled phase I/II CodeBreak 100 trial support the efficacy of sotorasib in certain patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC).

Dermatological adverse events (dAEs) associated with apalutamide, though common, can be managed with topical steroids with or without oral antihistamines, reports a study.